Ongoing challenges to finding people with Parkinson’s disease for epidemiological studies: A comparison of population-level case ascertainment methods

详细信息    查看全文

• 作者：M. Anne Harris^a ; ^{harris.m.anne@gmail.com"" rel=""nofollow} ; Mieke Koehoorn^b ; Kay Teschke^b
• 关键词：Parkinson&#x2019 ; s disease ; Levodopa ; Epidemiologic methods ; Data collection ; Case ascertainment
• 刊名：Parkinsonism and Related Disorders
• 出版年：2011
• 出版时间：July 2011
• 年：2011
• 卷：17
• 期：6
• 页码：464-469
• 全文大小：341 K

文摘

Background

Locating Parkinson’s disease cases for epidemiological studies has long been challenging. Self reports, secondary records of physician diagnosis and drug tracer methods each exhibit known disadvantages but have rarely been compared directly. Prescriptions of levodopa have in some studies been considered to comprise a reasonable proxy for Parkinson’s disease diagnosis. We tested this assumption by comparing three methods of population-level case ascertainment.

Design

We compared the number of Parkinson’s disease cases in British Columbia derived from self-reports in the 2001 Canadian Community Health Survey to those obtained from administrative records of filled levodopa prescriptions and to Parkinson’s disease diagnoses from physician visit billing and hospital discharge records in 1996 and 2005. We directly compared a case definition based on levodopa prescriptions with a definition based on records of physician diagnosis by calculating positive predictive value and sensitivity.

Results

Crude prevalence estimates ranged from approximately 100 to 200 per 100,000. Levodopa-based case definitions overestimated prevalence, while physician- and hospital-record-based case definitions provided lower prevalence estimates compared to survey derived estimates. The proportion of levodopa users with a diagnosis of Parkinson’s disease declined from 62 % to 52 % between 1996 and 2005. This decrease was most dramatic among women (64 % –44 % ) and those under age 65 (54 % –39 % ).

Conclusions

Sex and age trends suggest increasing use of levodopa among patients with conditions other than Parkinson’s disease, such as restless legs syndrome. Increased non-Parkinson’s levodopa use decreases the efficiency of levodopa as a Parkinson’s disease case tracer.